Abstract Complete resection of head and neck cancers with negative surgical margins improves the prognosis of the disease and decreases the recurrence rate. Near-infrared fluorescence-guided surgery of head and neck cancer is a rapidly evolving field that represents an invaluable tool for tumor detection and resection. Here, we present a literature review of the principles of near-infrared fluorescence imaging and its use in head and neck cancer surgery. We discuss important studies in both animal models and humans that have been carried out up to this point. We also outline the important fluorescent molecules and devices used in head and neck fluorescence imaging-guided surgery. Although near-infrared fluorescence-guided surgery for head and neck cancers showed efficacy in animal models, its use in humans is limited by the small number of fluorescent probes that are approved for clinical use. However, it is considered as a novel surgical aid that helps delineate tumor margins preoperatively and could spare patients from the added morbidity that is associated with additional surgery or chemoradiation. In addition, it is a useful tool to detect sentinel lymph nodes as well as metastatic lymph nodes.
Introduction
Worldwide, there are 600,000 new cases of head and neck cancer and 300,000 deaths each year [1] . Surgery is considered one of the main treatments for head and neck cancers and it has the best overall survival rate compared to radiotherapy and chemotherapy. Complete resection of the tumor tissue, detection of lymph nodes metastases and preservation of healthy tissue during head and neck cancer surgery are major issues that strongly influence the patient prognosis. Additionally, these factors affect the functional and physiological integrity of the head and neck region with considerable impacts on multiple facets of patient life [2] .
The development of near-infrared optical fluorescent techniques for diagnosis, treatment and follow-up of head and neck cancer is a growing field that provides real-time information regarding the presence, location and dimensions of the cancer tissue and/or metastasis through creation of a specific contrast between normal and cancer tissue. This contrast could be the result of tumor-induced morphologic and biochemical alterations that alter optical properties of tissues and lead to tumor-specific auto-fluorescence [3] . Furthermore, fluorescence can be achieved through targeting head and neck tumors by fluorescent probes that bind to specific receptors on cancer cells.
Orthotopic xenograft animal models were used to test novel applications of near-infrared fluorescence imagingguided surgery for head and neck cancers. Multiple studies were also performed in humans to evaluate the role of nearinfrared fluorescence imaging-guided surgery for head and neck tumors detection and resection. Several different fluorescent probes have been proposed to target head and neck cancers cells in animal models using near-infrared fluorescent imaging. For clinical translation of these results, however, very expensive and long lasting safety and reglementary issues should be addressed for each probe. Here, we present an overview of the use of nearinfrared fluorescence imaging in head and neck cancer surgery in animal models and its clinical applications in humans. We also outline the most important fluorescent molecules and devices used in head and neck fluorescence imaging-guided surgery.
Principles of in vivo near-infrared fluorescence imaging
Fluorescence is a process by which molecules absorb the excitation light and re-emit light of a longer wavelength after a brief interval of time. Light is produced from a spectrally resolved light source such as filtered broadband source, light-emitting diode or laser diode. The light emitted from the excited fluorophore is then captured by a charge-coupled device camera, with special care taken to filter the huge excess of photons coming from the excitation light. Near-infrared fluorescence imaging focuses on the detection of exogenous contrast agents that emit fluorescence between 700 and 900 nm. Because light is poorly absorbed by living tissues in this spectral window, nearinfrared imaging can provide real-time detection of exogenous fluorescent contrast agents at depths that usually do not exceed 1 cm [4, 5] . In parallel, endogenous fluorescence (autofluorescence) imaging can also be of interest. In fact, variations in the levels and depth of endogenous fluorophores can be present in cancer-induced biochemical changes, such as increases in NADH, decreases in FAD concentration, and altered elastin and keratin compositions. It can be also related to the shielding of the autofluorescence of the extracellular matrix that occurs during the thickening of epithelial tissues, which occurs during tumor development. Consequently, autofluorescence profiles are of specific interest because changes in metabolic activity and cellular interactions could be reflected by spectral alteration in the fluorescence signal [6, 7] . In addition to autofluorescence, narrow band imaging (NBI) which is based on a modification of the standard white light spectrum by optical filters that narrow the bandwidth of transmitted light through an endoscope giving a blue light that penetrates less deeply into tissue, gives the operator a good resolution of superficial structures like submucosal vessels that could show an abnormal vasculature in early cancerous lesions [8, 9] . Finally, other imaging techniques like lugol chromoendoscopy, confocal endoscopy and endocytology have been reported to be useful for detection of early-stage head and neck squamous cell carcinoma [10] . However, these imaging techniques with autofluorescence and NBI are mainly used to guide biopsies and to detect suspicious precancerous lesions, whereas exogenous near-infrared induced florescence is used in tumor resection and metastasis detection [3, 11, 12] .
Head and neck cancer near-infrared fluorescent contrast agents
Multiple strategies have been proposed for head and neck fluorescence imaging-guided surgery. For clinical translation of these strategies, pharmacokinetic studies must be performed for each fluorophore or fluorophore conjugate that targets specific receptors in cancer tissue. Indocyanine green (ICG) was one of the first fluorescent dyes tested for fluorescence imaging-guided surgery. ICG is an untargeted dye that clears from the tumor at a different rate than from the surrounding tissue. Because of its passive lymphatic drainage, and of its passive diffusion after extravasation, ICG has already shown promise for sentinel lymph node detection by passive targeting through its enhanced permeability and retention effect. However, its value for delineation of head and neck tumor margins is limited because it is considered as a blood pool agent that is not inherently specific for any tumor receptor [5, [13] [14] [15] [16] [17] . For these reasons, a targeted probe would provide real-time, intra-operative distinction of the molecular edge between cancer and adjacent normal tissue. The benefit would be in potentially decreasing the incidence of a positive surgical tumor margin.
For clinical translation, an optimal targeted fluorescent probe should have good distribution, high affinity toward its target and a fast clearance from the bloodstream, to allow efficient accumulation at the tumor and rapid acquisition of images with high contrast [5, 12, 13] . One of the most important targets of fluorescent probes is epidermal growth factor receptor (EGFR) which is overexpressed in 80-90 % of head and neck squamous cell carcinoma cases [18] . The Cetuximab antibody labeled with a near-infrared fluorophore is commonly used in head and neck fluorescence imaging-guided surgery. It is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human EGFR and is widely used in the treatment of head and neck squamous cell carcinoma, combined with other chemotherapeutic agents [18, 19] . Panitumumab is another probe that targets EGFR. It is a recombinant, fully humanized monoclonal antibody that has the advantage of presenting lower risk of eliciting an immune response in humans than Cetuximab [19, 20] . EGFR antibodies have also been conjugated with quantum dots, which are semiconductor nanocrystals (diameter 1-10 nm). When coupled with fluorophores, quantum dots present the advantage of producing near-infrared fluorescence with strong tissue penetrating ability, low absorbance by in vivo tissue, high light stability, high fluorescence quantum yield and minimal interference from normal tissue autofluorescence, but they cannot be used for human applications because of their chemical composition [20, 21] . Panitumumab and Cetuximab are conventional antibodies that show slow blood clearance, high accumulation in the liver and limited tumor penetration. Consequently, nanobodies, which are smaller functional antigen-binding fragments (15 kDa) derived from heavy chain antibodies, have been explored. They show highly specific binding to EGFR and ensure efficient distribution and tissue penetration, as well as rapid clearance from the body. When combined with fluorophores, they retain the ability to delineate head and neck tumors and lymph node metastases in head and neck cancer fluorescence imagingguided surgery [12, 22] . Finally, EGFR can be targeted by fluorophore-labeled recombinant human EGF, but this presents the risk of EGFR receptor activation that promotes the malignant phenotype [23] .
Another target for fluorescent probes used in head and neck cancer fluorescence imaging-guided surgery, is avb3 integrin, which plays an important role in cancer-associated angiogenesis, cell proliferation, migration and metastasis. It is widely expressed on neoendothelial cells and in some tumors including head and neck squamous cell carcinoma [24] [25] [26] . RAFT-c(-RGDfK-) 4 (regioselectively addressable functionalized template-arginine-glycine-aspartic acid) is a peptide-like scaffold that holds four cyclo(-RGDfK-) (cRGD) motifs. It was shown that this molecule targets avb3 integrin in vitro and in vivo and could be coupled with multiple fluorophores [27] [28] [29] [30] [31] [32] . Like EGFR antibodies, RGD could also be coupled with quantum dots as an alternative way to target avb3 integrin in head and neck cancer fluorescence imaging-guided surgery [21] .
Finally, other probes showed interesting results in head and neck cancer targeting such as fluorescent deoxyglucose probes that detect increased glucose uptake by the glucose transporter 1 (GLUT-1), which shows upregulation in head and neck cancer [23, 33] . VEGF was also a target of fluorescent probes comprising bevacizumab, which is an anti-VEGF antibody, that was conjugated to optically active fluorophores and resulted in adequate disease detection in the surgical setting [34] . Lastly, transferrin receptor, which is overexpressed in head and neck squamous cell carcinoma, was targeted using a near-infrared fluorescent transferrin conjugate that was able to identify and delineate head and neck tumors in mice [35] .
Although head and neck cancer-specific targeting remains a challenge, numerous commercial near-infrared fluorophores exist. They are largely based on the cyanine chemical structure with specific modifications by each manufacturer. Porphyrins, squaraine, boron dipyrromethane, benzo[c]heterocycles and xanthenes are also known classes of near-infrared fluorophores. Fluorophores can be readily conjugated to a protein or ligand of interest for specific in vivo targeting through conjugation at a lysine residue or N-terminal [5, 13, 36] .
Imaging systems used in head and neck cancer fluorescence-guided surgery
In addition to fluorescent contrast agents, a suitable camera system has to be developed for each application. Several near-infrared fluorescence imaging devices are now available for pre-clinical and clinical studies of head and neck fluorescence imaging-guided surgery. The FLARE TM (Frangioni Lab, Beth Israel Deaconess Medical Center, MA, USA) imaging system was used in animal studies, and the Mini-FLARE TM system, which is an optimized version for clinical studies, was used to guide sentinel lymph nodes fluorescent detection [12, 17] . The photodynamic eye camera system (Hamamatsu, Germany) also showed the ability to detect lymph drainage pattern and sentinel lymph nodes in humans [15] . The HyperEye Medical System (Mizuho Medical Co, Ltd, Tokyo, Japan) has been used in fluorescent tumor delineation in humans after systemic administration of ICG, but no histological studies were performed on tumor margins [37] . SPY imaging system (Novadaq, Ontario, Canada) is another device used to image and guide head and neck cancer resection in orthotopic animal models [21, 22] . Finally, the FluoSTIC preclinical device and the promising novel commercial fluorescence imaging system version, Fluostick TM (Fluoptics, Grenoble, France), are hand-held near-infrared cameras that have been miniaturized and optimized for oral oncologic procedures in humans [4] .
Use of near-infrared fluorescence imaging in head and neck cancer surgery in animal models
Like any novel treatment, head and neck cancer nearinfrared florescence imaging-guided surgery was first tested in animals before humans. Mice were the animal of choice to test this novel surgical aid because they are small in size, easy to handle and relatively inexpensive. Athymic nude mice were most commonly used because they are considered a suitable host for the development of implanted human head/neck cancer cells. In addition, their hairlessness decreases the attenuation of the fluorescence signal emission [38] . Multiple subcutaneous and orthotopic mouse models of head and neck cancer were developed. The advantage of orthotopic models is that they provide specific interactions between cancer cells and their native environment. This can consequently influence molecular, pathologic and clinical features of orthotopic tumors that become representative of human head and neck tumors [39] [40] [41] .
Near-infrared fluorescence imaging-guided surgery showed promising results for intraoperative fluorescence demarcation of head and neck tumors in both orthotopic and subcutaneous cell line xenografts. Tumor resections were performed under real-time guidance of fluorescence imaging, and there was an adequate correlation between the fluorescence signal and tumor extension on analysis of histological sections [12, 19, 23, 34, [42] [43] [44] [45] . Moreover, near-infrared fluorescence imaging in the surgical bed helped to identify fluorescent cancer residues that could remain unidentified if resection was performed exclusively under visual guidance. This had a positive impact on the recurrence-free survival rate of mice in comparison with mice that underwent tumor resection without any aid of fluorescence imaging (Fig. 1) (Atallah et al., submitted) . Furthermore, the use of optical imaging for detection of cervical lymph node metastases showed important value in orthotopic mouse models in which squamous cell carcinoma metastases were found on histological sections in all cervical lymph nodes that showed a fluorescence signal [12, 19, 23, [42] [43] [44] . In addition, no tumor was found in the negative lymph nodes on haematoxylin-eosin or immunohistochemical staining analysis [23] . Lastly, fluorescence imaging was used to detect distant pulmonary head and neck squamous cell carcinoma metastases. This could be considered an important tool in the management of head and neck cancers because distant metastasis is a contraindication to surgical therapy [19] .
Current practice and perspectives of near-infrared fluorescence imaging use in head and neck cancer surgery in humans
One of the first applications of head and neck cancer near-infrared fluorescence imaging-guided surgery in humans was sentinel lymph node biopsy after peritumoral injection of unconjugated ICG. This showed results that are equivalent to radioactive tracers, without the disadvantages of the lack of real-time intraoperative visual information and the need for a nuclear physician [15, 16, 46] . Moreover, premixing ICG with human serum albumin (HSA) to generate ICG:HSA complexes improved the fluorescent properties and retention in the sentinel lymph node owing to an increased hydrodynamic diameter (Fig. 2) [17, 47] . However, sentinel lymph node was only detectable after exposure of the neck structures following subplatysmal flap elevation, which is considered as a limiting factor for the nearinfrared fluorescence imaging in comparison to radioactive tracers that can detect sentinel lymph node preoperatively. We think that the relatively low depth sensitivity of the current generation of near-infrared imaging systems should be improved in the near future. ICG was also used to delineate head and neck tumors and lymph node metastases in humans, 30-60 min after intravenous administration [37] . All tumors and lymphatic metastases displayed bright fluorescence emissions that clearly contrasted with the normal structures. Fluorescence imaging was very useful to detect metastatic lymph nodes that were not palpable, and not visible macroscopically, in the retropharyngeal space [37] . Precautions have to be taken in tumor margin demarcation using ICG because accumulation of ICG may not be limited to cancerous tissues. In fact, ICG would also be expected to accumulate in inflammatory tissues and areas of surgical trauma that could partly hamper specificity in the initial phase of enhanced permeability and retention effect. However, these effects occur at much lower levels and retention in tumors is greatly increased owing to defective architecture of lymphatic drainage [48, 49] . Autofluorescence has also been used to define tumor margins, but the study was performed on punch biopsies of several sites from ex vivo human specimens. Sensitivity and specificity of the discrimination of normal tissue from cancerous tissue were evaluated by correlating histopathologic diagnosis with visual impression and were 91 and 86 %, respectively [6] . The use of head and neck cancer near-infrared fluorescence imaging-guided surgery in humans is limited by the small number of fluorescent probes that are approved for clinical use. Although ICG is considered a blood pool agent that is not inherently specific for any tumor, it is the only near-infrared fluorescent agent that has been used in clinical applications of head and neck cancer surgery because it is EMA (European Medicines Agency) and FDA (US Food and Drug Administration) approved as a near-infrared fluorescent contrast agent. Pharmacokinetics, pharmacodynamics and clinical toxicity studies have to be performed to analyze additional fluorescent probes that have shown efficient targeting of head and neck cancers in animal models. Owing to the complexity of the clinical translation process, we believe that repurposing of fluorescent molecules such as ICG and specific head and neck cancer-targeting probes such as anti-EGFR antibodies, which are already approved for clinical use, is a safe and cost-efficient way to develop new clinically approved fluorescent probes. In addition, more fluorescence imaging devices optimized for both open and endoscopic head and neck cancer surgery have to be developed.
Conclusion
Technological developments of near-infrared fluorescence imaging-guided cancer surgery have led to promising preclinical and clinical results. In head and neck cancer surgery, it is considered an invaluable tool to delineate tumors and to detect metastasis in animal models because of the real-time feedback and the contrast that it offers. In humans, it also showed encouraging results, but further development depends on the regulatory approval of nearinfrared optical devices and fluorescent targeted probes for clinical use. It will certainly lead to significant improvements in the surgical techniques regarding optimization of tumor margins, detection of residual disease and identification of lymph node metastases.
